iiinova — where your digital self keeps evolving

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 07/10/2026

🆕 Obesity Part 1: Collaboration with @rheumnow.bsky.social 🔵 GLP-1 Receptor Agonist Therapy in #Rheumatology 💉 ⚖️ Effects through weight loss + possible weight-independent effects 🫀 Impact on Multiple Organ Systems 🎲 RCT Data of GLP-1 RA Therapy in OA & PsA #RheumSky #Obesity #OA #PsA #GLP1

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 27/09/2026

Enjoyed speaking at our annual Duke Lupus Community Event yesterday on “Understanding Lupus Labs” 🩸🧪 #Lupus #PatientEducation #HealthLiteracy #RheumSky

040

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 10/09/2026

🆕 Visual Abstract with Healio 🎨 #Deucravacitinib in Psoriatic Arthritis: POETYK PsA-2 🎲 Phase 3 RCT of Deucravacitinib vs PBO 💊 Deucravacitinib = oral, selective TYK2 inhibitor 🥇 1st FDA-approved TYK2i for PsA Healio Article 🔗: vist.ly/5hps8 #RheumSky #DermSky #PsoriaticArthritis

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 18/08/2026

🆕 Gout Part 2: In Collaboration with Rheum Now @rheumnow.bsky.social Approach to Treatment of Gout 🔵 💊 Acute Treatment Options 💎 Urate Lowering Therapy 🫘 Renal Dose Adjustment for CKD #Gout #Rheumatology #RheumSky

011

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 07/07/2026

Factors Associated with BME: 👩 Female Sex ⚖️ Elevated BMI 🤰Pregnancy 🏃 Intense Physical / Occupational Activity 💡 Bone Marrow Edema ≠ AS! Overreliance on BME as diagnostic for axSpA can lead to misdiagnosis, especially in women, those with high occupational physical activity or high BMI.

110

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 07/07/2026

🆕 Visual Abstract with Healio Rheum 🟢 Bone Marrow Edema (BME) in the General Population 💡Key Takeaway: BME is NON-specific, and was seen in up to *30%* of healthy people (N >11,000) 📝 Bressem et al, Lancet Rheum 🔗: tinyurl.com/BMEHealio #Rheumatology #RheumX #Radiology

271

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 15/06/2026

🆕 Phase 3 RCT of #Brepocitinib (TYK2-JAK1 inhibitor) vs PBO in #Dermatomyositis (The VALOR Trial) 🔥 ⌛ Rapid onset: improvements as early as wk 4 💪 All pts had both active muscle + skin disease 📈 Improvement in myositis activity, GC tapering #Myositis #Rheumatology #DermSky #RheumSky #Dermatology

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 11/05/2026

🆕 Visual Abstract with Healio Rheum 🟢 GLP1 Receptor Agonist Use in #PsoriaticArthritis • Ixekizumab (IXE; Taltz) + Tirzepatide (GLP1) was superior to IXE alone in improving PsA disease activity 📝: by Merola et al (A&R) 🔗: tinyurl.com/glp1psa #GLP1 #Rheumatology #RheumX

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 21/01/2026

Sorry to hear the lack of support. Especially as it is a rare condition, I understand. Can check the American Behçet's Disease Association (ABDA) out online and whether any virtual support groups, and maybe CreakyJoints has some information too.

110

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 21/01/2026

Thank you for sharing! One of my goals is to help the general medical audience better recognize/ identify rheumatic conditions— including #Behcets!

110

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 07/01/2026

🆕 Visual Abstract w/ Healio Rheumatology 🟢 #Telitacicept in Systemic Lupus • telitacicept: TACI-Fc fusion protein which targets BLyS/APRIL • telitacicept: ⇡ response rate vs PBO 📖: van Vollenhoven et al, NEJM 📎: tinyurl.com/telitacicepthealio #Lupus #MedSky #RheumSky @gohealio.bsky.social

030

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 10/12/2025

🆕 Approach to Rheum Labs! 🧪 With the current #rheumatology workforce shortage, better education is needed to increase yield of new patient referrals from referring clinicians: 1️⃣ Joint Pain: when should one refer to #Rheum? 2️⃣ ANA: when should an #ANA be checked? #MedSky #RheumSky #PositiveANA

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 06/11/2025

I think this one looks clearer… the text is darker on this one!

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 05/11/2025

🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋 Just Released: Nov 3 #ACR25 🔥 🔸Review organ-specific treatment recommendations 🔸Steroid & HCQ Use Guidance 🔸Management of Comorbidities ➠ Read the Full Guideline here: acr.tw/47mkegj #RheumSky #SLE #Rheumatology

296

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 29/10/2025

🆕 Clinical Year in Review at #ACR25 By Dr. Bryant England @unmc.bsky.social 🔶 Review the most impactful studies in #Rheumatology from the past year! ❓ Any studies you would add to the list? #RheumSky #MedSky #YearInReview

053

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 28/10/2025

🆕 Secrets & Pearls of #Rheumatology at #ACR25 | Part 1 by Dr. Janet Pope 🖐️ Cutaneous Pathology SLE/DM 🧴 Tips for SLE 💪 Cancer Screening in Myositis 🩸 Laboratory Testing 🥶 Raynaud's / Scleroderma 👀 Sjogrens Disease #RheumSky #MedSky #Lupus #Myositis #Scleroderma #Sjogrens

0136

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 26/10/2025

🆕 ACR 2025 Guidelines for Treatment of Systemic Lupus Erythematosus 🦋 #ACR25 #Lupus #RheumSky

1148

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 02/10/2025

🆕 Collaboration with RheumNow 🔵 *3-Part Series on Interstitial Lung Disease* Part 3️⃣: Treatment of #ILD 💊 Medication Options for Rx of ILD 🫁 How to Treat Different ILD Subtypes 🚶🏻‍♀️Holistic Approach to Management ❌🚬 #RheumSky #PulmSky #IPF #Rheum #InterstitialLungDisease

131

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 17/09/2025

🆕 Collaboration with RheumNow 🔵 3-Part Series on Interstitial Lung Disease Part 2: Diagnosis & Subtypes of #ILD 👩🏻‍⚕️ What to look for on Physical Exam 🧪 Serologic Testing & Diagnostic Workup 🫁 Differentiating ILD Subtypes on Imaging #RheumSky #PulmSky #MedSky #InterstitialLungDisease

161

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 06/08/2025

🆕 Behçet's Disease: Let’s explore this multi-system #vasculitis 💫 👄 Oral and Genital Ulcers 🩸 DVT, Arterial Aneurysm 👁️ Uveitis 🧠 Neurologic Involvement 🖐️ Cutaneous Disease / Pathergy #RheumSky #Behcets #Rheumatology

Infographic showing different organ systems affected by Behcets: oral/genital ulcers, skin, vascular, GI, neurologic, ocular and more.

011

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 06/08/2025

So often for FUO consults with ID and Heme/Onc 😂

020

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 08/05/2025

🆕 2024 ACR Guidelines for Screening, Treatment and Management of Lupus Nephritis 🫘 • Just Released: May 7, 2025 🔥 🔸 New Recommendations for Triple Therapy for Class III/IV + V Lupus Nephritis 🦋 🔸 Reduced ⇣ Dose of PO Steroids after IV Pulse! 💊 #LupusNephritis #RheumSky #NephSky #Lupus

072

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 29/03/2025

Oh sounds interesting! Look forward to reading that.

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 27/03/2025

🆕 PJP Prophylaxis in #Rheumatology 🫁 🔹Discuss risk factors for PJP infection 🔹Risk Stratify: CD4 count <200 or ALC <500 = ⇡Risk 🔹Review Treatment options and when to stop PPx? #MedSky #RheumSky #PulmSky #PJP

140

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 19/03/2025

💫 Check out the new Rheum Madness x Rheum One Pagers bracket infographic! 🎉🏀📟 📖 Read most pivotal, innovative studies in #rheum in past 2 yrs 🎙️ Listen to the Rheum Madness podcasts 🏀 Submit Brackets before April 1 @rheummadness.bsky.social @davidleverenz.bsky.social @larneson.bsky.social

096

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 12/02/2025

🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial Phase 3 RCT: Obi vs PBO 🫘 Pts w/ SLE nephritis Class III/IV ± 5 🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids) 📊 Obi: ⇡rate of renal response and improved renal outcomes #LupusNephritis #RheumSky #NephSky #MedSky #Lupus

12616

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 18/12/2024

Yes good Q whether earlier targeting in the B-cell pathway with inebilizumab will make a significant difference with broader B cell depletion! Wonder if anyone else on #RheumSky has thoughts!

000

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 16/12/2024

🆕 Visual Abstract with Healio Rheumatology 🟢 🔥 New Therapy for IgG4-Related Disease: INEBILIZUMAB 💉 RCT of inebilizumab (anti-CD19) vs placebo 👥 Adult pts with IgG4-RD involving ≥ 2 organs 📊 Results:⇣flare rate,⇡remission #IgG4RD #RareDiseases #Rheumatology #Inebilizumab

061

Reposted by Mithu Maheswaranathan, MD

Sonali J. Bracken, MD, PhD @sjbracken.bsky.social · 08/12/2024

Happy holidays from the Duke Rheum crew ❄️ ⛄️ 🎄 @mithurheum.bsky.social

171

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 09/12/2024

Had so much fun! Thanks for hosting us #DukeRheum #Rheumatology ❄️🎄🎁

010

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 04/12/2024

Excited to have the opportunity to present on Physician #Burnout in Rheumatology at our division Grand Rounds today. Thankful many advocates have been voices on this important topic in our current healthcare climate & trend of physicians exiting clinical medicine!

2142

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 27/11/2024

That’s wild! The journal should help the authors make one if desired

010

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 18/11/2024

🆕 #ACR24 | Updated Guidelines for Lupus Nephritis Treatment & Management 🫘 Highlights 🔶 • Critical role of renal biopsy • Differences for treatment by LN Class • Adjunctive Rx w/ HCQ & RAASi • GC pulse ⇢ *moderate/low* dose PDN #Lupus #NephSky #RheumSky #Rheumatology #MedSky

05725

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 18/11/2024

Yes! It’s an abbreviation for placebo.

010

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 18/11/2024

#ACR24 Lupus Nephritis CARE • By Dr. Maria Dall'Era (UCSF) Review of #LupusNephritis 🫘 ▪️Rx TRIPLE therapy ▪️belimumab vs voclosporin ▪️low level proteinuria (even *UPCR <0.5*) can STILL be associated with disease activity (Class III/IV/V) #Lupus #RheumSky #NephSky

13212

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 17/11/2024

🆕 The Great Debate at #ACR24: Is Mixed Connective Tissue Disease (MCTD) a distinct disease entity? 🗳️ Final Vote (n=430 votes) • 51% = MCTD *is* a unique disease • 49% = MCTD is not a unique disease #MixedConnectiveTissueDisease #Rheumatology #RheumSky #MCTD

2184

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 17/11/2024

Clinical Year in Review at #ACR24 Presented by Dr. Michael Pillinger • Review some of the most impactful studies in Rheumatology from the past year! #MedSky #Rheumatology #RheumSky

14722

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 17/11/2024

Thank you for adding me! sounds good — that’s a good point too we may have growing interest on #RheumSky and need multiple starter packs to add everyone!!! #Rheumatology #ACR24

120

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 17/11/2024

Hii please add me! @kristenyoung.bsky.social started a #rheumatology starter pack already, too - should we use that one to have everyone in one central location? Maybe she can link it here! #ACR24

110

Mithu Maheswaranathan, MD @mithurheum.bsky.social · 16/11/2024

Congratulations to @sjbracken.bsky.social & all the ACR Distinguished Fellow award recipients at #ACR24 🥇 Anyone who knows Sonali knows how dedicated and hardworking she is — from her research to patient care — working to improve the lives of patients with #scleroderma! #DukeRheum

Photo of the 2024 ACR Distinguished Fellow award recipients on stage

1111